Literature DB >> 27082853

Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231.

Anna De Blasio1, Riccardo Di Fiore1, Marco Morreale1, Daniela Carlisi2, Rosa Drago-Ferrante1, Mauro Montalbano2, Christian Scerri3, Giovanni Tesoriere4, Renza Vento1.   

Abstract

Triple-negative breast cancer (TNBC) is a clinically aggressive form of breast cancer that is unresponsive to endocrine agents or trastuzumab. TNBC accounts for ~10-20% of all breast cancer cases and represents the form with the poorest prognosis. Patients with TNBC are at higher risk of early recurrence, mainly in the lungs, brain and soft tissue, therefore, there is an urgent need for new therapies. The present study was carried out in MDA-MB-231 cells, where we assessed the role of caspase-8 (casp-8), a critical effector of death receptors, also involved in non‑apoptotic functions. Analysis of casp-8 mRNA and protein levels indicated that they were up-regulated with respect to the normal human mammalian epithelial cells. We demonstrated that silencing of casp-8 by small interfering-RNA, strongly decreased MDA-MB-231 cell growth by delaying G0/G1- to S-phase transition and increasing p21, p27 and hypo-phosphorylated/active form of pRb levels. Surprisingly, casp-8-knockdown, also potently increased both the migratory and metastatic capacity of MDA-MB‑231 cells, as shown by both wound healing and Matrigel assay, and by the expression of a number of related-genes and/or proteins such as VEGFA, C-MYC, CTNNB1, HMGA2, CXCR4, KLF4, VERSICAN V1 and MMP2. Among these, KLF4, a transcriptional factor with a dual role (activator and repressor), seemed to play critical roles. We suggest that in MDA-MB‑231 cells, the endogenous expression of casp-8 might keep the cells perpetually cycling through downregulation of KLF4, the subsequent lowering of p21 and p27, and the inactivation by hyperphosphorylation of pRb. Simultaneously, by lowering the expression of some migratory and invasive genes, casp-8 might restrain the metastatic ability of the cells. Overall, our findings showed that, in MDA-MB-231 cells, casp-8 might play some unusual roles which should be better explored, in order to understand whether it might be identified as a molecular therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27082853     DOI: 10.3892/ijo.2016.3474

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.

Authors:  Ines Müller; Elwira Strozyk; Sebastian Schindler; Stefan Beissert; Htoo Zarni Oo; Thomas Sauter; Philippe Lucarelli; Sebastian Raeth; Angelika Hausser; Nader Al Nakouzi; Ladan Fazli; Martin E Gleave; He Liu; Hans-Uwe Simon; Henning Walczak; Douglas R Green; Jiri Bartek; Mads Daugaard; Dagmar Kulms
Journal:  Mol Cell       Date:  2020-01-22       Impact factor: 17.970

2.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

3.  Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.

Authors:  Deeksha Malhan; Alireza Basti; Angela Relógio
Journal:  NPJ Syst Biol Appl       Date:  2022-05-12

4.  Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2.

Authors:  Daniela Carlisi; Anna De Blasio; Rosa Drago-Ferrante; Riccardo Di Fiore; Giuseppina Buttitta; Marco Morreale; Christian Scerri; Renza Vento; Giovanni Tesoriere
Journal:  Cell Death Discov       Date:  2017-12-04

5.  Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.

Authors:  Rosa Drago-Ferrante; Francesca Pentimalli; Daniela Carlisi; Anna De Blasio; Christian Saliba; Shawn Baldacchino; James Degaetano; Joseph Debono; Gordon Caruana-Dingli; Godfrey Grech; Christian Scerri; Giovanni Tesoriere; Antonio Giordano; Renza Vento; Riccardo Di Fiore
Journal:  Oncotarget       Date:  2017-04-25

Review 6.  Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer Quae Exempli Causa.

Authors:  Maria-Ancuta Jurj; Mihail Buse; Alina-Andreea Zimta; Angelo Paradiso; Schuyler S Korban; Laura-Ancuta Pop; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 5.923

7.  scMAGeCK links genotypes with multiple phenotypes in single-cell CRISPR screens.

Authors:  Lin Yang; Yuqing Zhu; Hua Yu; Xiaolong Cheng; Sitong Chen; Yulan Chu; He Huang; Jin Zhang; Wei Li
Journal:  Genome Biol       Date:  2020-01-24       Impact factor: 13.583

Review 8.  Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.

Authors:  You-Take Oh; Shi-Yong Sun
Journal:  Biomolecules       Date:  2021-03-26

9.  Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.

Authors:  Mohammed Moustapha Anwar; Manal Shalaby; Amira M Embaby; Hesham Saeed; Mona M Agwa; Ahmed Hussein
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

10.  Promotion of tumorigenesis by miR-1260b-targeting CASP8: Potential diagnostic and prognostic marker for breast cancer.

Authors:  Sunyoung Park; Jungho Kim; Yoonjung Cho; Sungwoo Ahn; Geehyuk Kim; Dasom Hwang; Yunhee Chang; Sunmok Ha; Yeonim Choi; Min Ho Lee; Hyunju Han; Sunghyun Kim; Seung Il Kim; Hyeyoung Lee
Journal:  Cancer Sci       Date:  2022-03-31       Impact factor: 6.518

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.